利用模型整合生物等效 (MIBE) 解决监管问题,免除重复生物等效研究-用皮格瑞尔进行的案例研究
Mathangi Gopalakrishnan1, Adithya Karthik Bhattiprolu2, Joga Gobburu1
1Center for Translational Medicine, University of Maryland Baltimore, Baltimore, MD, USA.
Journal of clinical pharmacology
|December 17, 2025
概括
模型整合生物等价性 (MIBE) 方法成功地放弃了对克洛皮多格雷尔二硫酸盐的重复研究. 这种药物动力学建模证实了尽管早期采样,但生物等价性,简化了药物开发.
科学领域:
- 药理动力学和药物开发
- 监管科学 监管科学
- 生物制药生物制药公司
背景情况:
- 基于模型的策略,包括模型综合生物等效 (MIBE) 方法,对于高效的药物开发越来越重要.
- MIBE使决策成为可能,并可能导致对生物等价性研究的豁免.
- 使用MIBE方法评估了克洛皮多格雷尔二硫酸盐300毫克片.
研究的目的:
- 为了证明MIBE方法对克洛皮多格雷尔二硫酸盐300毫克片的成功应用.
- 解决关键生物等价性研究中早期药理动力学采样方面的监管问题.
- 评估截断采样对生物等价性评估和AUC0-inf.的影响.
主要方法:
- 进行了一项关键的生物等价性研究,对药物动力学采样进行了长达12小时的试验 (药物半衰期约为6小时).
- 使用试点研究数据 (长达24小时) 开发了一个群体药理动力学模型,用于禁食和食条件.
- 通过使用开发的模型来评估生物等价性,对完整的药物动力学概况 (最多10个半衰期) 进行了模拟.
主要成果:
- MIBE方法成功预测了药理动力学参数,并证实了平均生物等价性.
- 模拟表明,生物等效的90%置信区间处于80%-125%的可接受范围内.
- 截止至12小时的抽样并没有影响关键研究结果的解释性.
结论:
- MIBE方法有效地支持放弃重复的禁食和食生物等价性研究,用于克洛皮多格雷尔二硫酸盐300毫克片.
- 这一战略通过减少对广泛临床研究的需求来简化药物产品的开发.
- MIBE为生物等价性评估的监管决策提供了一个强大的框架.
相关概念视频
01:13Bioequivalence studies: Biowaivers
206
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
206
01:16Bioequivalence: Overview
1.6K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.6K
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
141
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
141
01:28Drug Products: Biologics, Biosimilars and Interchangeables
217
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
217
01:15Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
162
Body:Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
162
01:17Equivalence: In Vitro and In Vivo Bioequivalence
193
Body:Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts.
193